The latest instructions: Regulate medical behavior! Surround the medical mess!

On September 1st, the 15th meeting of the Central Committee for Comprehensive and Deepening Reform was held, and it was noteworthy that the meeting considered and adopted the Opinions on the Implementation of Promoting the Innovation and Development of Foreign Trade, the Opinions on revitalizing Higher Education in the Midwest in the New Era, the Implementation Opinions on Standardizing the Development of Private Compulsory Education, the Guidance on Further Standardizing Medical Behavior and Promoting Rational Medical Examinations, and the Opinions on Further Promoting the Classification of Household Waste.
this year, the state has issued relevant documents around regulating medical behavior and promoting rational medical examination.
February 25, the State Council of the CPC Central Committee, opinions on deepening the reform of the medical security system, proposed to standardize the diagnosis and treatment of medical institutions and medical personnel, implement a prescription review system, and promote rational drug use.
June 30, the General Office of the State Council", "Guidance on promoting the reform of the regulatory system of medical security funds", pointed out that we should strengthen the guidance and audit of clinical diagnosis and treatment behavior of designated medical institutions, and strengthen the supervision in advance and in advance.
deepen the reform of the supply side of medical services.
speed up the comprehensive reform of public hospitals, establish and improve the modern hospital management system, and standardize the behavior of diagnosis and treatment.
July 16, the General Office of the State Council issued a notice on the key tasks for deepening the reform of the medical and health system in the second half of 2020, stressing that the pilot work of "credit plus comprehensive supervision" should be carried out.
formulate policy documents on comprehensive regulatory accountability and supervision mechanisms for the medical and health industries.
formulated a number of provisions to strengthen the construction of health supervision system, and promote the standardization of supervision institutions.
to further standardize medical behavior and promote reasonable medical examination.
about changes in medical behaviour, the pharmaceutical industry is of course the focus, in addition to constraining medical practitioners.
On June 5, 2020, the State Drug Administration publicly solicited the opinions of the Measures for the Administration of the Record of Pharmaceutical Representatives (Trial) (Draft for Comments), which, in order to implement the Notice issued by the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council on the Deepening of the Reform of the Review and Approval System to Encourage the Innovation of Pharmaceutical Medical Devices, regulates the practice of pharmaceutical representatives.
The Measures state that drug market license holders shall not be encouraged or implied to engage in illegal and illegal activities by pharmaceutical representatives, assign drug sales tasks to pharmaceutical representatives, and require pharmaceutical representatives to collect payments and process purchase and sale bills.
the transformation of the drug generation is indeed urgent.
Not long ago, the industry will often burst out a certain drug generation in the hospital was caught or even about a pharmaceutical company in the hospital to carry out gold sales were reported news, not long ago, a listed company sales costs are abnormally high exposure by the industry, but also sit real now the pharmaceutical industry, although after rectification, but still chaos of the status quo, it is no wonder that the drug tender pain killer, a sharp price reduction.
From the start of the national harvest of 4 plus 7, to a province of two diseases a penny winning bid, including pharmaceutical enterprises, tender departments of the pharmaceutical people were surprised to find that dozens of points of decline, some pharmaceutical companies are still living well.
to the just-concluded three batches of national rotation, there are still selected enterprises to promote their products "good space, profit enough!" In this side of the strong price reduction side still have enterprises everywhere to show off the cost of the background, it can be expected that the next price reduction will be very high and faster.
Even though, the intensive introduction of drug policy, will make pharmaceutical practitioners feel uncomfortable, it is because the previous in the gold environment of the "comfort zone" stayed too long, now the market is not the market of the year, and then to the drug dealer's thinking to engage in the pharmaceutical industry, and then in the name of "help, on the quantity" to harass doctors, and even in the name of pseudo-CSO to open invoices to prove the true behavior of self-sale, no doubt is self-indulgent.
Looking back, the issuance in October 2017 of the Opinions on Deepening the Reform of the Review and Approval System to Encourage Drug Medical Device Innovation is undoubtedly a watershed, with policies requiring new drug research and development to be in line with international standards, joining ICH, new drugs requiring new global concepts, promoting the MAH system, and liberalizing the filing of applications from clinical trial institutions.
also called for accelerated approval of innovative drugs and the introduction of international innovative drugs.
to speed up the health care catalog negotiations, health care funds to change birds, talk about guaranteed access to the hospital.
these policies are undoubtedly what the country is moving forward and doing step by step in three years' time.
Just like the current volume of procurement: consistency evaluation in promoting the development of CRO, over-evaluation as long as full competition on the development of national procurement, not through consistent evaluation can not avoid the provincial volume of procurement skynet, are price reduction, rather than evaluation of no market, it is better to evaluate the allocation of the market, from a certain extent to promote the transformation of pharmaceutical enterprises enthusiasm, to avoid pharmaceutical companies think that "do is to find death, do not do is to die" excessive ideas.
On the one hand, through the system construction to speed up the improvement of medical behavior, on the other hand, through the volume of procurement to fully pressure prices, compression of sales links to control sales costs to clear the soil of the gray space of medicine, although for pharmaceutical enterprises, 2020 is difficult.
difficult, but also learn to medulate wealth, low-key life.
pharmaceutical companies should now look for ways to provide the best treatment options, how to choose effective drugs, from doctor-centered to patient-centered transformation, to provide patient-specific products to help them treat.
industry that develops/produces drugs needs to return to its essence, so that the quality and effectiveness of the drug can solve the problem, in this precondition to comply with the laws of the market, so that the price/price/price ratio back to the market recognized position.
the essence of the work done, and then talk about marketing / market / access / price these, otherwise, will always be speculation on the road, will not last.
.